Breaking News, Trials & Filings

Elite Begins Bioequivalence Study

Will test abuse-deterrent formulation

Elite Pharmaceuticals has begun dosing of a pilot bioequivalence study in healthy volunteers for ELI-201, the company’s twice daily abuse deterrent oxycodone/naltrexone product.

A pivotal bioequivalence study for a second abuse deterrent product is scheduled to begin dosing in January 2014, and the pivotal bioequivalence study for ELI-201 is scheduled to begin dosing in March 2014. The bioequivalence studies for these opioid abuse deterrent products are being conducted under the direction of Camargo Pharmaceutical Services.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters